Insmed Incorporated

INSM

US4576693075

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2026-01-14 pm EST			5-day change	1st Jan Change
163.46 ^USD	-0.16%		-7.12%	-6.08%

Jan. 13	Insmed Insider Sold Shares Worth $351,341, According to a Recent SEC Filing	MT
Jan. 13	Insmed Insider Sold Shares Worth $3,247,349, According to a Recent SEC Filing	MT

Insmed Incorporated Provides Revenue Guidance for the Full Year 2025

Published on 01/09/2026 at 09:24 am EST

S&P Capital IQ

Insmed Incorporated

-0.16%

Insmed Incorporated provided revenue guidance for the full year 2025. For the year, the company expected total revenues of $606.4 million as compared to $363.7 million reported a year ago.

Latest news about Insmed Incorporated

Jan. 13	Insmed Insider Sold Shares Worth $351,341, According to a Recent SEC Filing	MT
Jan. 13	Insmed Insider Sold Shares Worth $3,247,349, According to a Recent SEC Filing	MT
Jan. 12	Insmed Incorporated Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-12-2026 03:00 PM
Jan. 09	Insmed Incorporated Provides Revenue Guidance for the Full Year 2025	CI
Jan. 09	Sector Update: Health Care Stocks Rise Pre-Bell Friday	MT
Jan. 09	Sector Update: Health Care	MT
Jan. 09	Insmed Reports Higher Preliminary 2025 Revenue; Shares Up Pre-Bell	MT
Jan. 08	Insmed Insider Sold Shares Worth $746,711, According to a Recent SEC Filing	MT
Jan. 08	Insmed Insider Sold Shares Worth $549,494, According to a Recent SEC Filing	MT
Jan. 08	RBC Lifts Price Target on Insmed to $197 From $195, Keeps Outperform Rating	MT
Jan. 06	Insmed Insider Sold Shares Worth $15,293,422, According to a Recent SEC Filing	MT
Jan. 06	UBS Adjusts Price Target on Insmed to $215 From $223, Maintains Buy Rating	MT
Dec. 22	Insmed Incorporated(NasdaqGS:INSM) added to NASDAQ-100 Index	CI
Dec. 19	Insmed Insider Sold Shares Worth $1,786,457, According to a Recent SEC Filing	MT
Dec. 18	Top Midday Decliners	MT
Dec. 18	Insmed's Pipeline Can Deliver Potential Gains Despite Brensocatib Setback, RBC Says	MT
Dec. 18	Mizuho Adjusts Price Target on Insmed to $212 From $256, Maintains Outperform Rating	MT
Dec. 18	Inflation Took a Chill Pill
Dec. 18	Top Premarket Decliners	MT
Dec. 18	RBC Lowers Price Target on Insmed to $195 From $215, Keeps Outperform Rating	MT
Dec. 18	Analyst recommendations: American Express, Merck, Rivian, Albemarle, Micron…
Dec. 17	Stocks to Watch : Micron, MillerKnoll, HireQuest, Insmed	DJ
Dec. 17	Insmed scraps development of sinus drug after mid-stage study failure	RE
Dec. 17	Insmed Halts Brensocatib Development in CRSsNP After Trial Miss; Shares Fall After Hours	MT
Dec. 17	Insmed provides clinical and business update	RE

Insmed Incorporated is a global biopharmaceutical company. The Company's first commercial product, ARIKAYCE (amikacin liposome inhalation suspension), is used for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. Its pipeline includes clinical-stage programs, brensocatib and TPIP, as well as other early-stage research programs. Brensocatib is a small molecule, oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP1), which is developing for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases, including chronic rhinosinusitis without nasal polyps (CRSsNP). TPIP is an inhaled formulation of the treprostinil prodrug treprostinil palmitil, which offers a differentiated product profile for pulmonary hypertension associated with interstitial lung disease (PH-ILD) and pulmonary arterial hypertension (PAH).

Employees

1,271

Sector

Biotechnology & Medical Research

Calendar

Feb. 18 - Q4 2025 Earnings Release (Projected)

More about the company